# Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

> **NCT04188964** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kyowa Kirin Pharmaceutical Development Ltd** · enrollment: 16 (actual)

## Conditions studied

- X-linked Hypophosphatemia (XLH)

## Interventions

- **DRUG:** Burosumab

## Key facts

- **NCT ID:** NCT04188964
- **Lead sponsor:** Kyowa Kirin Pharmaceutical Development Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-26
- **Primary completion:** 2023-10-04
- **Final completion:** 2024-03-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04188964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04188964, "Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04188964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*